When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
VTGN - VistaGen clarifies design of late-stage study of lead candidate in anxiety disorder
VistaGen Therapeutics Inc.
Based on FDA feedback, VistaGen (NASDAQ:VTGN) has clarified key aspects of its planned Phase 3 clinical trial evaluating lead drug PH94B, a rapid-onset neurosteroid nasal spray, for the acute treatment of anxiety in adults with social anxiety disorder (SAD), a Fast Track-tagged indication in the U.S.
More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, Stocks on the move,